Attorney Docket No.: DIV of HA0721A (DIV IV)

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper reterred to as being attached or enclosed) is being transmitted by facsimile to the United States Patent and Trademark Office, Official Fax (703) 746-4000 on the date shown below

Tina Markee Type or print name Vinc Marles

January 4, 20<u>05</u> Date

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

LLOYD ET AL.

EXAMINER: RAO, DEEPAK

APPLICATION NO: 10/823,987

Group Art Unit: 1624

FILED: April 14, 2004

FOR: POTASSIUM CHANNEL INHIBITORS AND METHOD

Assistant Commissioner for Patents Washington, D.C. 20231 Box Issue Fee

AMENDMENT UNDER RULE 1.312

Commissioner:

Applicants request amendment of claim 18 (as renumbered by the Examiner's Amendment mailed October 4, 2004, to correct a non-substantive error therein. By way of this amendment, the definition of R5, which was rendered extraneous by a preceding restriction requirement, is removed. A full text of the claims, as amended to date in the prosecution and further amended by this pleading, is attached hereto.

The required filing fees are authorized to be charged, or any overpayment thereof credited to the Assignee's Deposit Account No. 19-3880.

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-4014

Date: January 4, 2005

Respectfully submitted

Deanna L. Baxam

Attorney for Applicants

Reg. No. 45,266